Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas

International Journal of Cancer

Volumn 69, Issue 3, 1996, Pages 205-211

  Gasparini, Giampietro ^a   Bonoldi, Emanuela ^a   Viale, Giuseppe ^b   Verderio, Paolo ^b   Boracchi, Patrizia ^b   Panizzoni, Gino A ^a   Radaelli, Umberto ^c   Di Bacco, Alessandra ^b   Guglielmi, Rosa B ^a   Bevilacqua, Pierantonio ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c St Paolo Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CD31 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; TUMOR VASCULARIZATION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; EVALUATION STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 8944227508     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6     Document Type: Article

References (24)

1. ANDERSON, P.K., BORGAN, O., DILL, R.D. and KEIDING, N., Statistical models based on counting processes. Springer, New York (1993).
2. BOOCOCK, C.A., CHARNOCK-JONES, D.S., SHARKEY, A.M., MCLAREN, J., BARKER, P.J., WRIGHT, K.A., TWENTYMAN, P.R. and SMITH, S.K., Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J. nat. Cancer Inst., 87, 506-516 (1995).
3. BRESLOW, N.E., and DAY, N.E., Statistical methods in cancer research, Vol. 1, IARC Scientific Publication 32. International Agency for Research on Cancer, Lyon (1980).
4. CANCER COMMITTEE OF THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS. Staging Announcement. FIGO Cancer Committee, Gynecol. Oncol., 25, 383-385 (1986).
5. CORDON-CARDO, C., O'BRIEN, J.P., BOCCIA, J., CASALS, D., BERTINO, J.R. and MELAMED, M.R., Expression of the multidrug resistance gene product P-glycoprotein in human normal and tumour tissues. J. Histochem. Cytochem., 9, 1277-1287 (1990).
6. FOLKMAN, J., Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature (Med.), 1, 27-31 (1995).
7. GASPARINI, G., BARBARESCHI, M., BORACCHI, P., VERDERIO, P., CAFFO, O., MELI, S., DALLA PALMA, P., MARUBINI, E. and BEVILACQUA, P., Tumor angiogenesis predicts clinical outcome of node- positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J. Sci. Amer., 1, 131-141 (19956).
8. GASPARINI, G., BEVILACQUA, P., BONOLDI, E., TESTOLIN, A., GALASSI, A., VERDERIO, P., BORACCHI, P., GUGLIELMI, R.B. and PEZZELLA, F., Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin. Cancer Res., 1, 1375-1383 (1995a).
9. GASPARINI, G., WEIDNER, N., BEVILACQUA, P., MALUTA, S., DALLA PALMA, P., CAFFO, O., BARBARESCHI, M., BORACCHI, P., MARUBINI, E. and POZZA, F., Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. clin. Oncol., 12, 454-466 (1994).
10. HANLEY, J.A., and MCNEIL, B.J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143, 29-36 (1982).
11. HARRELL, F., CALIFF, R.M., PRYOR, D.B., LEEK, K.L. and ROSATI, R.A., Evaluating the yield of medical tests. J. amer. med. Ass., 247, 2543-2548 (1982).
12. HOLLINGSWORTH, H.C., KOHN, E.C., STEINBERG, S.M., ROTHENBERG, M.L. and MERINO, M.J., Tumor angiogenesis in advanced stage ovarian carcinoma. Amer. J. Pathol., 147, 33-41 (1995).
13. HUANG, A. and WRIGHT, J.A., Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Oncogene, 9, 491-499 (1994).
14. KACINSKI, B.M., CARTER, D., and MITTAL, K., Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often withcoexpression of CSF-1. Amer. J. Pathol., 137, 135-147 (1990).
15. MACAULAY, V.M., FOX, S.B., ZHANG, H., WHITEHOUSE, R.M., LEEK, R.D., GATTER, K.C., BICKNELL, R. and HARRIS, A.L., Breast cancer angiogenesis and tamoxifen resistance. Endocrine-Related Cancer, 2, 97-103 (1995).
16. NAGY, J.A., MORGAN, E.S., HERZBERG, K.T., MARSEAU, E.J., DVORAK, A.M. and DVORAK, H.F., Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res., 55, 376-385 (1995).
17. OZOLS, R.F., GARVIN, A.J., COSTA, J., SIMON, R.M. and YOUNG, R.C., Advanced ovarian cancer: Correlation of histologic grade with response to therapy and survival. Cancer, 45, 572-581 (1980).
18. SENGER, D.R., GALLI, S.J., DVORAK, A.M., PERUZZI, C.A., HARVEY, V.S. and DVORAK, H.F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, 983-985 (1983).
19. STEINER, R., Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM assay) In: P.S. Weiss and R. Langer, (eds.), Angiogenesis: Key Principles - Science, Technology, Medicine, pp. 449-454, Birkhauser, Basle (1992).
20. SWENERTON, K., JEFFREY, J., STUART, G., ROY, M., KREPART, G., CARMICHAEL, J., DROUIN, P., STANIMIR, R., O'CONNELL, G., MACLEAN, G., KIRK, M.E., CANETTA, R., KOSKI, B., SHELLEY, W., ZEE, B. and PATER, J., Cisplatin-cyclophosphamide versus carboplatincyclophosphamide in advanced ovarian cancer: Randomized phase III study of the National Cancer Institute of Canada clinical trials group. J. clin. Oncol., 10, 718-726 (1992).
21. VAN DIEST, P.J., ZEVERING, J.P., ZEVERING, L.C. and BAAK, J.P.A., Lack of prognostic value of microvessel counts in FIGO 3 and 4 cisplatin treated ovarian cancer patients. Pathol. Res. Pract., 191, 25-30 (1995).
22. WEIDNER, N., Intratumoral microvessel density as a prognostic factor in cancer. Amer. J. Pathol., 147, 1-11 (1995).
23. WINGO, P.A., TONG, T. and BOLDEN, S., Cancer statistics, 1995. CA Cancer J. Clin., 45, 8-30, (1995).
24. YEO, K.-T., WANG, H.H., NAGY. J.A., SIOUSSAT, T.M., LEDBETTER, S.R., HOOGEWERF, A.T., ZHOU, Y., MASSE, E.M., SENGER, O.R., DVORAK, H.F. and YEO, T.K., Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res., 53, 2912-2918 (1993).